Skip to main content
. 2022 Jan 24;45(2):61–65. doi: 10.1097/COC.0000000000000887

TABLE 4.

Change in Left Ventricular Ejection Fraction From Baseline During Trastuzumab-based Chemotherapy

n (%)
Reference Trastuzumab (N=27) Biosimilar Trastuzumab (N=12)
No decrease 7 (25.9) 4 (33.3)
Decrease of <10 points from baseline 14 (51.9) 6 (50.0)
Decrease of ≥10 points from baseline 6 (22.2) 2 (16.7)
<50 points and decrease of ≥10 points from baseline 1 (3.7) 1 (8.3)